Assessment of Anti-Nuclear Antibodies and Anti-Extractable Nuclear Antigen Levels in Breast Cancer Patients

Elif Aslan; Asmaa Abuaisha; Selman Emiroğlu; Mehmet Ali Dogan

Makale detayları

Assessment of Anti-Nuclear Antibodies and Anti-Extractable Nuclear Antigen Levels in Breast Cancer Patients

Yazarlar:

Elif Aslan | Asmaa Abuaisha | Selman Emiroğlu | Mehmet Ali Dogan

Yayıncı:

Igdir University

Ana Başlıklar:

Genetik İmmünoloji | Genetik (Diğer)

Dergi:

Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi Vol.14 Issue 2, pp.888-893

Belge Tipi:

Makale

Yayın Tarihi:

1/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001317819

pISSN:

2536-4618

Anahtar kelimeler:

Özet:

 Anti-nuclear antibodies ANAs are autoantibodies synthesized in response to the cell nucleus contents and use as biomarkers of systemic autoimmune diseases. Inflammation, apoptosis and necrosis of the cells are consequences that accompany breast cancer against which autoantibodies will be produced. In this study, we aimed to evaluate the presence of ANAs and anti-extractable nuclear antigens anti-ENAs in breast cancer. A total of 33 luminal A and luminal B breast cancer patients were assessed for presence of ANAs and anti-ENAs. All the patients had received hormone therapy at least for 6 months before the tests. Patients were screened to ANAs by indirect immunofluorescence on human epithelial type 2 HEp-2 cells. AESKUBLOTS ANA-17 comp kit was used to identify the concentrations of U1-snRNP, snRNPSm, SmD1, dsDNA, SS-ARo 60, SS-ARo 52, SS-BLa antibodies. Fifteen 45.5 patients were luminal A and 18 54.5 patients were luminal B. The median of age was 57 and the median of tumor size was 25. 19 57.6 patients had grade I or II and 14 42.4 had grade III. 3 patients had ANAs test positive. All the patients who had positive ANA test were luminal A breast cancer and had grade I or II tumors and positive lymph node, whereas, pathological tumor stage were varied. No statistically significant association was found between ANAs positivity and molecular subtype, age, body mass index BMI, grade, tumor stage or lymph node involvement. Moreover, there were negative correlations between the anti-U1-snRNP and anti-dsDNA with Ki-67 and a correlation between anti-snRNPSm and anti-SS-ARo 52 was found. Comparing with luminal A, anti-U1-snRNP and anti-snRNPSm concentrations were statistically significantly lower in luminal B tumors p 0.015 and 0.016 respectively. Patients who had high grade tumors showed low concentrations of anti-snRNPSm p0.027, whereas patients who had lymph node metastasis showed high concentrations of anti-U1-snRNP p0.031. ANAs positivity was more common in luminal A breast cancer patients compared with luminal B. Anti-U1-snRNP and anti-snRNPSm concentrations were lower in luminal B. Moreover, patients who had high grade tumors showed low concentrations of anti-snRNPSm, whereas those who had lymph node metastasis showed high concentrations of anti-U1-snRNP.

 Anti-nuclear antibodies ANAs are autoantibodies synthesized in response to the cell nucleus contents and use as biomarkers of systemic autoimmune diseases. Inflammation, apoptosis and necrosis of the cells are consequences that accompany breast cancer against which autoantibodies will be produced. In this study, we aimed to evaluate the presence of ANAs and anti-extractable nuclear antigens anti-ENAs in breast cancer. A total of 33 luminal A and luminal B breast cancer patients were assessed for presence of ANAs and anti-ENAs. All the patients had received hormone therapy at least for 6 months before the tests. Patients were screened to ANAs by indirect immunofluorescence on human epithelial type 2 HEp-2 cells. AESKUBLOTS ANA-17 comp kit was used to identify the concentrations of U1-snRNP, snRNPSm, SmD1, dsDNA, SS-ARo 60, SS-ARo 52, SS-BLa antibodies. Fifteen 45.5 patients were luminal A and 18 54.5 patients were luminal B. The median of age was 57 and the median of tumor size was 25. 19 57.6 patients had grade I or II and 14 42.4 had grade III. 3 patients had ANAs test positive. All the patients who had positive ANA test were luminal A breast cancer and had grade I or II tumors and positive lymph node, whereas, pathological tumor stage were varied. No statistically significant association was found between ANAs positivity and molecular subtype, age, body mass index BMI, grade, tumor stage or lymph node involvement. Moreover, there were negative correlations between the anti-U1-snRNP and anti-dsDNA with Ki-67 and a correlation between anti-snRNPSm and anti-SS-ARo 52 was found. Comparing with luminal A, anti-U1-snRNP and anti-snRNPSm concentrations were statistically significantly lower in luminal B tumors p 0.015 and 0.016 respectively. Patients who had high grade tumors showed low concentrations of anti-snRNPSm p0.027, whereas patients who had lymph node metastasis showed high concentrations of anti-U1-snRNP p0.031. ANAs positivity was more common in luminal A breast cancer patients compared with luminal B. Anti-U1-snRNP and anti-snRNPSm concentrations were lower in luminal B. Moreover, patients who had high grade tumors showed low concentrations of anti-snRNPSm, whereas those who had lymph node metastasis showed high concentrations of anti-U1-snRNP.

 Anti-nuclear antibodies ANAs are autoantibodies synthesized in response to the cell nucleus contents and use as biomarkers of systemic autoimmune diseases. Inflammation, apoptosis and necrosis of the cells are consequences that accompany breast cancer against which autoantibodies will be produced. In this study, we aimed to evaluate the presence of ANAs and anti-extractable nuclear antigens anti-ENAs in breast cancer. A total of 33 luminal A and luminal B breast cancer patients were assessed for presence of ANAs and anti-ENAs. All the patients had received hormone therapy at least for 6 months before the tests. Patients were screened to ANAs by indirect immunofluorescence on human epithelial type 2 HEp-2 cells. AESKUBLOTS ANA-17 comp kit was used to identify the concentrations of U1-snRNP, snRNPSm, SmD1, dsDNA, SS-ARo 60, SS-ARo 52, SS-BLa antibodies. Fifteen 45.5 patients were luminal A and 18 54.5 patients were luminal B. The median of age was 57 and the median of tumor size was 25. 19 57.6 patients had grade I or II and 14 42.4 had grade III. 3 patients had ANAs test positive. All the patients who had positive ANA test were luminal A breast cancer and had grade I or II tumors and positive lymph node, whereas, pathological tumor stage were varied. No statistically significant association was found between ANAs positivity and molecular subtype, age, body mass index BMI, grade, tumor stage or lymph node involvement. Moreover, there were negative correlations between the anti-U1-snRNP and anti-dsDNA with Ki-67 and a correlation between anti-snRNPSm and anti-SS-ARo 52 was found. Comparing with luminal A, anti-U1-snRNP and anti-snRNPSm concentrations were statistically significantly lower in luminal B tumors p 0.015 and 0.016 respectively. Patients who had high grade tumors showed low concentrations of anti-snRNPSm p0.027, whereas patients who had lymph node metastasis showed high concentrations of anti-U1-snRNP p0.031. ANAs positivity was more common in luminal A breast cancer patients compared with luminal B. Anti-U1-snRNP and anti-snRNPSm concentrations were lower in luminal B. Moreover, patients who had high grade tumors showed low concentrations of anti-snRNPSm, whereas those who had lymph node metastasis showed high concentrations of anti-U1-snRNP.

 Anti-nükleer antikorlar ANAs, hücre çekirdek içeriğine karşı üretilen otoantikorlardır ve sistemik otoimmün hastalıkların biyobelirteçleri olarak kullanılırlar. İnflamasyon, apoptoz ve hücre nekrozu, meme kanseri ile ilişkili olarak ortaya çıkan hücresel sonuçlardır ve bu duruma karşı otoantikorlar üretilebilir. Bu çalışmada, meme kanserinde ANAların ve anti-ekstrakte edilebilir nükleer antijenlerin anti-ENAs varlığını değerlendirmeyi amaçladık. Toplam 33 lümenal A ve lümenal B meme kanseri hastası, ANAların ve anti-ENAsın varlığı açısından değerlendirildi. Tüm hastalar, testlerden en az 6 ay önce hormon terapisi almışlardır. Hastalar, insan epitel tip 2 HEp-2 hücrelerinde endirekt immünoflorasansta ANAlar için taranmıştır. U1-snRNP, snRNPSm, SmD1, dsDNA, SS-ARo 60, SS-ARo 52, SS-BLa antikor konsantrasyonlarını belirlemek için AESKUBLOTS ANA-17 comp kiti kullanıldı. Onbeş hastanın 45.5 lümenal A ve 18 hastanın 54.5 lümenal B olduğu belirlendi. Ortalama yaş 57, tümör boyutu ise 25 tir. Hastaların 57.6sında I veya II derece, 42.4ünde III derece tümör vardı ve üç hasta ANA testi pozitifti. Pozitif ANA testi olan tüm hastalar lümenal A meme kanserliydi ve I veya II derece tümöre sahip olup pozitif lenf noduna sahipti; ancak patolojik tümör evresi değişkenlik gösteriyordu. ANA pozitifliği ile moleküler alt tip, yaş, vücut kitle indeksi VKİ, derece, tümör evresi veya lenf nodu tutulumu arasında istatistiksel olarak anlamlı bir ilişki bulunamamıştır. Ayrıca, anti-U1-snRNP ve anti-dsDNAnın Ki-67 ile negatif, anti-snRNPSm ve anti-SS-ARo 52nin ise pozitif bir korelasyonu bulunmuştur. Lümenal A ile karşılaştırıldığında, anti-U1-snRNP ve anti-snRNPSm konsantrasyonları lümenal B tümörlerinde istatistiksel olarak önemli ölçüde düşük bulunmuştur sırasıyla p 0.015 ve 0.016. Yüksek dereceli tümöre sahip hastalar, düşük anti-snRNPSm konsantrasyonları gösterirken, lenf nodu metastazına sahip olanlar yüksek anti-U1-snRNP konsantrasyonları sergilemiştir sırasıyla p0.027 ve 0.031. ANA pozitifliği, lümenal A meme kanseri hastalarında lümenal Bye kıyasla daha yaygın bulunmuştur. Anti-U1-snRNP ve anti-snRNPSm konsantrasyonları lümenal Bde daha düşüktür. Ayrıca, yüksek dereceli tümöre sahip hastalar düşük anti-snRNPSm konsantrasyonları gösterirken, lenf nodu metastazı olanlar yüksek anti-U1-snRNP konsantrasyonları sergilemiştir.

Makale detayları

Assessment of Anti-Nuclear Antibodies and Anti-Extractable Nuclear Antigen Levels in Breast Cancer Patients

Yazarlar:

Elif Aslan | Asmaa Abuaisha | Selman Emiroğlu | Mehmet Ali Dogan

Yayıncı:

Igdir University

Ana Başlıklar:

Genetik İmmünoloji | Genetik (Diğer)

Dergi:

Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi Vol.14 Issue 2, pp.888-893

Belge Tipi:

Makale

Yayın Tarihi:

1/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001317819

pISSN:

2536-4618

Anti-nuclear antibodies (ANAs)

Autoantibodies

Breast Cancer

Anti-Extractable Nuclear Antigens (ENAs)Anti-nükleer antikorlar (ANAs)

Otoantikorlar

Meme Kanseri

Anti-Çekilebilir Nükleer

Antijenler (ENAs)

Sayı

Makale detayları

Yazarlar: Elif Aslan | Asmaa Abuaisha | Selman Emiroğlu | Mehmet Ali Dogan

Yayıncı: Igdir University

Ana Başlıklar: Genetik İmmünoloji | Genetik (Diğer)

Dergi: Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi Vol.14 Issue 2, pp.888-893

Belge Tipi: Makale

Yayın Tarihi: 1/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001317819

pISSN: 2536-4618

Sayı

Yazarlar:

Elif Aslan | Asmaa Abuaisha | Selman Emiroğlu | Mehmet Ali Dogan

Yayıncı:

Igdir University

Ana Başlıklar:

Genetik İmmünoloji | Genetik (Diğer)

Dergi:

Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi Vol.14 Issue 2, pp.888-893

Belge Tipi:

Makale

Yayın Tarihi:

1/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001317819

pISSN:

2536-4618